$471 Million is the total value of Opaleye Management Inc.'s 39 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 54.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CMRX | Buy | CHIMERIX INC | $35,879,000 | +15.2% | 5,580,000 | +10.9% | 7.61% | +30.8% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS INC | $20,580,000 | +143.1% | 724,400 | +80.1% | 4.36% | +176.1% |
| TARA | Buy | PROTARA THERAPEUTICS INC | $17,996,000 | +1.6% | 2,650,000 | +3.6% | 3.82% | +15.4% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $11,696,000 | +99.9% | 342,000 | +3.6% | 2.48% | +127.0% |
| PRQR | Buy | PROQR THERAPEUTICS NV | $11,498,000 | -3.5% | 1,435,510 | +0.8% | 2.44% | +9.5% |
| STRO | Buy | SUTRO BIOPHARMA INC | $10,118,000 | -0.4% | 680,000 | +26.4% | 2.15% | +13.1% |
| MRUS | Buy | MERUS N.V. | $10,106,000 | +358.1% | 317,800 | +217.0% | 2.14% | +420.1% |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $9,534,000 | -0.7% | 883,602 | +6.1% | 2.02% | +12.8% |
| RETA | New | REATA PHARMACEUTICALS INCclass a | $8,702,000 | – | 330,000 | +100.0% | 1.85% | – |
| TCON | Buy | TRACON PHARMACEUTICALS INC | $8,462,000 | -13.2% | 3,055,000 | +21.3% | 1.80% | -1.4% |
| New | GINKGO BIOWORKS HOLDINGS INCclass a shares | $7,726,000 | – | 929,780 | +100.0% | 1.64% | – | |
| TELA | Buy | TELA BIO INC | $5,758,000 | -4.9% | 449,867 | +1.5% | 1.22% | +8.0% |
| New | HYPERFINE INC | $5,523,000 | – | 763,075 | +100.0% | 1.17% | – | |
| FDMT | New | 4D MOLECULAR THERAPEUTICS INC | $5,024,000 | – | 229,000 | +100.0% | 1.07% | – |
| NCNA | Buy | NUCANA PLCsponsored adr | $2,830,000 | +128.8% | 1,189,000 | +147.9% | 0.60% | +159.7% |
| SYBX | New | SYNLOGIC INC | $2,057,000 | – | 850,000 | +100.0% | 0.44% | – |
| LQDA | New | LIQUIDIA CORPORATION | $82,000 | – | 16,800 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.